sc 51089 has been researched along with rtki cpd in 1 studies
| Studies (sc 51089) | Trials (sc 51089) | Recent Studies (post-2010) (sc 51089) | Studies (rtki cpd) | Trials (rtki cpd) | Recent Studies (post-2010) (rtki cpd) |
|---|---|---|---|---|---|
| 41 | 1 | 19 | 744 | 0 | 257 |
| Protein | Taxonomy | sc 51089 (IC50) | rtki cpd (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0584 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ariff, MA; Mathivanan, P; Parker, R; Rudra, T; Taub, M | 1 |
1 other study(ies) available for sc 51089 and rtki cpd
| Article | Year |
|---|---|
Antagonism of the prostaglandin E2 EP1 receptor in MDCK cells increases growth through activation of Akt and the epidermal growth factor receptor.
Topics: Animals; Bridged Bicyclo Compounds; Caproates; Cell Proliferation; Dogs; ErbB Receptors; Heterocyclic Compounds, 3-Ring; Hydrazines; Ibuprofen; Kidney; Madin Darby Canine Kidney Cells; Oxazepines; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Prostaglandin E, EP1 Subtype; Receptors, Prostaglandin E, EP2 Subtype; Receptors, Prostaglandin E, EP4 Subtype; Signal Transduction; Tyrphostins | 2014 |